Device Trial Radar · NCT05304650
A Usability Study of External Neuromodulation With iTEAR100 Generation 2
Last checked: Nov 19, 2026Latest source record: Mar 31, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Planned (sponsor's estimate)
Start
Mar 1, 2022
Primary completion
Apr 30, 2022
Study completion Jun 15, 2022
Sponsor
- Lead sponsor
- Olympic Ophthalmics, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Mar 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Usability Study of External Neuromodulation With iTEAR100 Generation 2. A study which evaluates user ability to train and access the iTEAR100 device in a telehealth environment.
Conditions
- Dry Eye Syndromes
Interventions
iTEAR100Device
Controlled Stimulation External Nasal Nerve to stimulate tear production
Primary outcomes
What the sponsor says the trial is designed to measure.
- UsabilityTime frame: 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Olympic Ophthalmics
Issaquah, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.